Non-small cell lung cancer metastatic
Not recruitingStudy Comparing Acasunlimab and Pembrolizumab with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments
Study Comparing Acasunlimab and Pembrolizumab with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments
- Disease:Non-small cell lung cancer metastatic
- Substances:AcasunlimabAnakinra+8
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Acasunlimab
- Sponsor:Genmab A/S












